PHEN Clinical Trials Rally

Increasing the participation of African American men in prostate cancer clinical trials through education, awareness, support and collaborations. This portal provides clinical trials background information, details for specific trials, personal stories and other resources to support the Rally.

This information is not intended as medical advice for patients. Patients should consult their medical doctor for advice and recommendations about specific clinical trials.


"We must not be left behind with new prostate cancer treatments."

PHEN president and founder Thomas A. Farrington talks about his prostate cancer journey and the importance of African American men participating in clinical trials.

Information

Understanding the possible benefits for patients when participating in a clinical trial.

Clinical trials offer important and unique benefits to patients.

Information

Dr. J. Carter Presents Clinical Trials 101

Dr. Carter's brief video presentations provide basic information for patients to better understand clinical trials.

Information

What Are Clinical Trials?

Information that all patients need to know when considering enrolling into a clinical trial.

Information

CA209-9KD

This is a clinical research study for men with metastatic prostate cancer (cancer that has spread) that no longer responds to androgen deprivation therapy treatments that lower testosterone.

Information

IPATential150 Clinical Trial

This trial is for patients with metastatic castration-resistant Prostate Cancer who are eligible for, but have not yet begun, abiraterone (Zytiga) treatment.

Information

ARASENS Clinical Trials Summary

For men who have metastatic cancer and who have never been treated with chemotherapy or immunotherapy.

Information

Triton 2 Clinical Trial

For patients with metastatic castration resistant prostate cancer that is progressing following treatment with Zytiga, Xtandi, and taxane based chemotherapy

Information

Triton 3 Clinical Trial

For patients where hormone therapy no longer keeps the PSA from increasing (metastatic castration resistant prostate cancer) with evidence of BRCA1, BRCA2, or ATM genetic mutations or alterations

Information

ENACT Clinical Trial Summary

For patients considering active surveillance or currently undergoing active surveillance.

Information

EMBARK Clinical Trial Summary

For patients with a rising PSA after being treated with surgery, radiation or both.

Information

The TRUMPET Registry

For men whose prostate cancer has grown or spread despite use of hormonal treatments to lower their PSA; Known as castration-resistant prostate cancer.

Information

Low and Intermediate Risk Prostate Cancer

Clinical trials for patients who are diagnosed with low and intermediate risk prostate cancer. Patients may be in active surveillance or making a decision to begin active treatment

Information

High Risk Prostate Cancer

Clinical trials for patients diagnosed with high risk prostate cancer. Patients may be deciding on an active treatment protocol.

Information

Treated with Prostatectomy or Radiation

Clinical trials for patients who have been treated with surgery or radiation. Patients may be seeking to reduce the risk of recurrence following primary treatment or interested in quality of life studies.

Information

Recurrent Prostate Cancer

Clinical trials for patients who have a recurrence of prostate cancer following primary treatment with surgery or radiation. Patients may be seeking treatment options with recurrence following primary treatment.

Information

Castration Resistant Prostate Cancer (CRPC)

Clinical trials for patients whose PSA no longer responds to androgen deprivation therapy but prostate cancer has not metastasized. Patients who are seeking treatment options following a diagnosis of CRPC.

Information

Metastatic Castration Resistant Prostate Cancer (mCRPC)

Clinical trials for patients diagnosed with metastatic prostate cancer that no longer responds to androgen deprivation treatment. Patients who are seeking treatment options following a diagnosis of mCRPC.

Information
























PHEN,Inc. © 2018 All rights reserved